Clinical Trials in Atlanta

Showing 14121-14140 of 19,805 trials

ReliefLink: A Preventative Mobile Toolkit for Follow-Up Care of Psychiatric Patients

NCT02691221

The purpose of this study is to increase use and availability, as well as assess the feasibility of the ReliefLink (RL) application for use in conjunction with standard care to promote psychological health and prevent suicidal behavior.

Suicide, Suicidal Ideation

Emory University13 participantsStarted Apr 2016

Atlanta, Georgia, United States

COMPLETEDPhase 2< 1 mile

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

NCT02076178

This study is a Phase IIa, randomized, multi-site, two-arm, double-blinded study to evaluate the safety, tolerability, and acceptability of GSK1265744 long acting injectable formulation (744 LA) in adult male subjects. To evaluate the safety and tolerability of the injectable agent, 744 LA (800 milligrams (mg) dose administered at three time points at 12 week intervals) through Week 41 in HIV-uninfected men. Eligible participants will be randomized in a 5:1 ratio to receive 744 LA or matching placebo. Participants will receive daily oral 744 (30 mg tablets) or matching placebo for 4 weeks during the Oral Phase of the study, followed by a one week washout period. Following safety lab assessments from the Oral Phase, participants will enter the Injection Phase and receive Intramuscular (IM) injections of 744 LA or placebo at three time points at 12 week intervals. IM injections will consist of 800 mg of 744 or a matching control

Infection, Human Immunodeficiency Virus

ViiV Healthcare127 participantsStarted Mar 2014

San Francisco, California, United States • Washington D.C., District of Columbia, United States • Atlanta, Georgia, United States +7 more locations

ReliefLink: A Preventative Mobile Toolkit for Follow-Up Care of Psychiatric Patients

Study to Evaluate the Safety Tolerability and Acceptability of Long Acting Injections of the Human Immunodeficiency Virus (HIV) Integrase Inhibitor, GSK1265744, in HIV Uninfected Men (ECLAIR)

Find Trials by Condition in Atlanta

Enoxaparin Dosing in Obesity

Dose Escalation Study in Patients With Relapsed or Refractory DLBCL and MyD88 L265P Mutation

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

A Study to Evaluate the Effect of Camicinal on Gastroparesis Symptoms in Type 1 and 2 Diabetic Subjects With Gastroparesis

Targeting Inflammation Using Salsalate for Type 2 Diabetes-Stage II

Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

Safety, Pharmacokinetics and Preliminary Efficacy of Asimadoline in Pruritus Associated With Atopic Dermatitis

Safety and Efficacy Trial of Testosterone Undecanoate

Safety and Immunogenicity of H1N1 Vaccines in Adults Aged 18 Years and Older

Open-Label Study in Diabetic Foot Ulcers (DFU), to Evaluate Safety of 0.03% DSC127 Topical Gel in Chronic Use

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects Who Are Intolerant to Statins

A Phase II Study of GSK1363089 (Formerly XL880) for Papillary Renal-Cell Carcinoma (PRC)

Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

Clodronate With or Without Chemotherapy and/or Hormonal Therapy in Treating Women With Stage I or Stage II Breast Cancer

InterStim® Sacral Nerve Modulation Cycling Study

HOPE Demonstration Field Experiment Multisite Evaluation

To Investigate the Safety, Tolerability and Pharmacodynamics of GSK2890457 in Healthy Volunteers and Subjects With Type 2 Diabetes

International PFO Consortium